Viking Therapeutics announced the start of Phase 3 studies involving its injectable, GLP-1/GIP-targeted obesity drug, called ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...

Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding Therapeutic Applica ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

Sarepta Therapeutics is down 83.1% since the beginning of the year, and at $20.91 per share, it is trading 87.2% below its 52-week high of $163.85 from June 2024. Investors who bought $1,000 worth ...

Pharma Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients By Angus Liu Jun 16, 2025 10:58am ...

Investor Contact: Ian Estepan 617-274-4052 [email protected] Media Contacts: Tracy Sorrentino 617-301-8566 [email protected] Kara Hoeger 617-710-3898 [email protected] ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK ...

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.